Xintela recruits Rickard Mosell as Head of Business Development

On 12 September 2016, Xintela announces that Rickard Mosell has been recruited as Head of Business Development from October 1, 2016. Rickard Mosell will leave his current position as CEO of Ideon Innovation and will be responsible for Xintela's business development and financing. Rickard Mosell will also be a member of Xintela's management team.

Read as PDF

Rickard Mosell's acedemic background is in law and he has broad experience of innovation and business operations. Amongst other roles, he has been the CEO for Ideon Science Park in Lund – comprising approximately 370 companies with 2 700 employees – and his most recent appointment as CEO for the business incubator Ideon Innovation.  Overall, Rickard Mosell has been an advisor in business development, financing, marketing and legal aspects to approximately 10 000 start-up projects.

– It is vital going forward that Xintela has a strong focus on business development and we are confident that Rickard has the experience, the competence and the network needed.  He has long been a driving force in business development, sales and communication and has built up an extensive and significant network, both nationally and internationally. We are very happy to welcome Rickard back to Xintela, says the company's CEO Evy Lundgren-Åkerlund.

Rickard Mosell has previously been closely involved with Xintela. In 2009, he was a co-founder of the company and thereafter, until 2014, he was a member of the board.  

– I am really looking forward to being part of Xintela again and helping to develop a clear commercial focus for this exciting company. Of course it makes things easier that I already have a good understanding of the operations and that I know Evy previously, says Rickard Mosell.

Rickard Mosell will also join Xintela's management team which currently comprises the company's CEO Evy Lundgren-Åkerlund, Research Director Carl-Magnus Högerkorp, Finance Director Gunnar Telhammar and strategic advisor (and Chairman of the Board) Gregory Batcheller.

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel:+46 70-329 18 71
E-mail: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

Queries regarding trading with Xintela shares and warrants will be answered by the company’s Certified Adviser, Consensus Asset Management AB. Telephone: +46 31-745 50 00.

Media and Investor Relations related queries should be directed to:
Adam Lindblom, Laika Consulting
Tel: +46 73-062 20 13
E-mail: adam.lindblom@laika.se
www.laika.se

About Xintela 
Xintela AB (publ) is a Swedish biomedical company active in the fields of regenerative medicine and cancer, with a focus on cartilage damage and brain tumours.  The key to Xintela's business is the Company's patented marker technology, XINMARK™. Xintela's markers are specific proteins which sit as "recognition flags" on certain cell surfaces.  The markers make it possible to identify and quality assure cartilage cells and stem cells and also to select a certain type of stem cells which can develop into cartilage cells. Through this technology, Xintela can, in a unique way, quality assure stem cells for the repair of damaged cartilage. The XINMARK™-technology makes it also possible to direct antibody treatment to cells in glioblastoma brain tumours with the goal to slow down tumour growth. Xintela is listed on Nasdaq First North since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Consensus Asset Management AB.      

This information is information that Xintela AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of the contact persons set out above on 12 September 2016, at 2:00 p.m CET